Vertex Pharmaceuticals Stock Shows Volatility Amid Financial Updates

Vertex Pharmaceuticals has experienced notable changes in its stock price during early February 2026, with share values fluctuating in relation to its 52-week high and recent financial disclosures.

On February 6, 2026, Vertex shares finished trading at $477.92, marking a 4.17% increase compared to the previous session and outperforming other companies in the sector. Despite this gain, the closing price remained about 8% below the company's 52-week high, which was recorded in March 2025.

In the days leading up to this, Vertex stock had shown varied performance. On February 5, 2026, the stock declined by 2.49% to $458.81, underperforming the broader market and remaining more than 11% below its annual peak. The day before, on February 4, 2026, the stock rose by 1.05% to $470.52, also outperforming several biotech competitors but still trading under its highest value for the year.

As of February 2, 2026, the most recent closing price was $472.01. The company's 52-week trading range extended from a low of $362.50, reached in August 2025, to the high of $519.68 set in March 2025.

What the numbers show

• Vertex reported Q4 2024 revenue of $2.91 billion, up 16% year-over-year
• Cystic fibrosis drugs contributed $2.72 billion in Q4 2024
• Adjusted EPS for Q4 2024 was $3.98, below the $4.02 estimate
• GAAP net income for Q2 2025 was $1.0 billion; non-GAAP net income was $1.2 billion
• Cash and marketable securities totaled $12.0 billion as of June 30, 2025

Vertex’s financial reports have highlighted both revenue growth and profitability. In the fourth quarter of 2024, the company reported revenue of $2.91 billion, representing a 16% increase compared to the same period in the previous year. The majority of this revenue came from its cystic fibrosis treatments, which generated $2.72 billion.

The company’s adjusted earnings per share for the fourth quarter of 2024 were $3.98, which did not meet the $4.02 estimate. In the second quarter of 2025, Vertex reported a GAAP net income of $1.0 billion and a non-GAAP net income of $1.2 billion, reversing net losses from the same quarter in 2024. The company also reported holding $12.0 billion in cash and marketable securities as of the end of June 2025.

Vertex stated that its full-year 2025 revenue guidance remained unchanged, with expectations between $11.85 billion and $12.0 billion. This guidance was reiterated in August 2025, according to company statements.

Throughout the past year, Vertex’s stock price has moved within a range of $362.50 to $519.68. The lowest point was reached in August 2025, while the highest was recorded in March 2025. Recent trading activity has kept the share price below the annual peak but above the lowest levels of the year.

* This article is based on publicly available information at the time of writing.